MICROBIX BIOSYSTEMS INC (MBX.CA) Fundamental Analysis & Valuation

TSX:MBX • CA59501P1045

Current stock price

0.24 CAD
-0.01 (-4%)
Last:

This MBX.CA fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

3

1. MBX.CA Profitability Analysis

1.1 Basic Checks

  • In the past year MBX has reported negative net income.
  • MBX had a negative operating cash flow in the past year.
  • In multiple years MBX reported negative net income over the last 5 years.
  • The reported operating cash flow has been mixed in the past 5 years: MBX reported negative operating cash flow in multiple years.
MBX.CA Yearly Net Income VS EBIT VS OCF VS FCFMBX.CA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 2M -2M 4M -4M -6M

1.2 Ratios

  • MBX has a Return On Assets of -11.67%. This is amongst the best in the industry. MBX outperforms 86.96% of its industry peers.
  • MBX's Return On Equity of -16.05% is amongst the best of the industry. MBX outperforms 86.96% of its industry peers.
Industry RankSector Rank
ROA -11.67%
ROE -16.05%
ROIC N/A
ROA(3y)1.04%
ROA(5y)3.95%
ROE(3y)1.4%
ROE(5y)5.76%
ROIC(3y)N/A
ROIC(5y)N/A
MBX.CA Yearly ROA, ROE, ROICMBX.CA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -20 -40 -60 -80

1.3 Margins

  • MBX has a Gross Margin of 46.74%. This is in the better half of the industry: MBX outperforms 78.26% of its industry peers.
  • In the last couple of years the Gross Margin of MBX has grown nicely.
  • MBX does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 46.74%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.11%
GM growth 5Y3.66%
MBX.CA Yearly Profit, Operating, Gross MarginsMBX.CA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20 -20 40 -40 60

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

5

2. MBX.CA Health Analysis

2.1 Basic Checks

  • MBX does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • MBX has more shares outstanding than it did 1 year ago.
  • The number of shares outstanding for MBX has been increased compared to 5 years ago.
  • MBX has a worse debt/assets ratio than last year.
MBX.CA Yearly Shares OutstandingMBX.CA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M 100M
MBX.CA Yearly Total Debt VS Total AssetsMBX.CA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M

2.2 Solvency

  • MBX has an Altman-Z score of 1.39. This is a bad value and indicates that MBX is not financially healthy and even has some risk of bankruptcy.
  • Looking at the Altman-Z score, with a value of 1.39, MBX belongs to the top of the industry, outperforming 82.61% of the companies in the same industry.
  • MBX has a Debt/Equity ratio of 0.25. This is a healthy value indicating a solid balance between debt and equity.
  • MBX's Debt to Equity ratio of 0.25 is fine compared to the rest of the industry. MBX outperforms 65.22% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.25
Debt/FCF N/A
Altman-Z 1.39
ROIC/WACCN/A
WACC7.72%
MBX.CA Yearly LT Debt VS Equity VS FCFMBX.CA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 10M 20M

2.3 Liquidity

  • A Current Ratio of 7.51 indicates that MBX has no problem at all paying its short term obligations.
  • MBX has a better Current ratio (7.51) than 91.30% of its industry peers.
  • A Quick Ratio of 4.48 indicates that MBX has no problem at all paying its short term obligations.
  • With an excellent Quick ratio value of 4.48, MBX belongs to the best of the industry, outperforming 91.30% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 7.51
Quick Ratio 4.48
MBX.CA Yearly Current Assets VS Current LiabilitesMBX.CA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5M 10M 15M 20M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

5

3. MBX.CA Growth Analysis

3.1 Past

  • The earnings per share for MBX have decreased strongly by -320.71% in the last year.
  • The Revenue for MBX has decreased by -27.23% in the past year. This is quite bad
  • Measured over the past years, MBX shows a quite strong growth in Revenue. The Revenue has been growing by 12.05% on average per year.
EPS 1Y (TTM)-320.71%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-233.33%
Revenue 1Y (TTM)-27.23%
Revenue growth 3Y-0.87%
Revenue growth 5Y12.05%
Sales Q2Q%-30.2%

3.2 Future

  • Based on estimates for the next years, MBX will show a very strong growth in Earnings Per Share. The EPS will grow by 52.75% on average per year.
  • MBX is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 29.96% yearly.
EPS Next Y33.33%
EPS Next 2Y52.75%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year35.93%
Revenue Next 2Y29.96%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
MBX.CA Yearly Revenue VS EstimatesMBX.CA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 10M 20M 30M 40M
MBX.CA Yearly EPS VS EstimatesMBX.CA Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 0 0.02 -0.02 0.04 0.06

More info and screens

Find the best growth stocksShow best growing peers

4

4. MBX.CA Valuation Analysis

4.1 Price/Earnings Ratio

  • MBX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • The Price/Forward Earnings ratio is 3.39, which indicates a rather cheap valuation of MBX.
  • Based on the Price/Forward Earnings ratio, MBX is valued cheaper than 95.65% of the companies in the same industry.
  • When comparing the Price/Forward Earnings ratio of MBX to the average of the S&P500 Index (23.84), we can say MBX is valued rather cheaply.
Industry RankSector Rank
PE N/A
Fwd PE 3.39
MBX.CA Price Earnings VS Forward Price EarningsMBX.CA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
MBX.CA Per share dataMBX.CA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.05 0.1 0.15

4.3 Compensation for Growth

  • The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • MBX's earnings are expected to grow with 52.75% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y52.75%
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. MBX.CA Dividend Analysis

5.1 Amount

  • MBX does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

MBX.CA Fundamentals: All Metrics, Ratios and Statistics

MICROBIX BIOSYSTEMS INC

TSX:MBX (3/13/2026, 7:00:00 PM)

0.24

-0.01 (-4%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-12
Earnings (Next)05-13
Inst Owners0.43%
Inst Owner ChangeN/A
Ins Owners14.85%
Ins Owner ChangeN/A
Market Cap33.25M
Revenue(TTM)16.76M
Net Income(TTM)-4.27M
Analysts80
Price Target0.51 (112.5%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-44.44%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 3.39
P/S 1.98
P/FCF N/A
P/OCF N/A
P/B 1.25
P/tB 1.45
EV/EBITDA N/A
EPS(TTM)-0.03
EYN/A
EPS(NY)0.07
Fwd EY29.46%
FCF(TTM)-0.03
FCFYN/A
OCF(TTM)-0.03
OCFYN/A
SpS0.12
BVpS0.19
TBVpS0.17
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -11.67%
ROE -16.05%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 46.74%
FCFM N/A
ROA(3y)1.04%
ROA(5y)3.95%
ROE(3y)1.4%
ROE(5y)5.76%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.11%
GM growth 5Y3.66%
F-Score2
Asset Turnover0.46
Health
Industry RankSector Rank
Debt/Equity 0.25
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 42.46%
Cap/Sales 4.56%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 7.51
Quick Ratio 4.48
Altman-Z 1.39
F-Score2
WACC7.72%
ROIC/WACCN/A
Cap/Depr(3y)83.66%
Cap/Depr(5y)119.48%
Cap/Sales(3y)5.99%
Cap/Sales(5y)7.06%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-320.71%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-233.33%
EPS Next Y33.33%
EPS Next 2Y52.75%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-27.23%
Revenue growth 3Y-0.87%
Revenue growth 5Y12.05%
Sales Q2Q%-30.2%
Revenue Next Year35.93%
Revenue Next 2Y29.96%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-242.37%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year4.01%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-13227.2%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-462.4%
OCF growth 3YN/A
OCF growth 5YN/A

MICROBIX BIOSYSTEMS INC / MBX.CA Fundamental Analysis FAQ

What is the ChartMill fundamental rating of MICROBIX BIOSYSTEMS INC (MBX.CA) stock?

ChartMill assigns a fundamental rating of 4 / 10 to MBX.CA.


What is the valuation status of MICROBIX BIOSYSTEMS INC (MBX.CA) stock?

ChartMill assigns a valuation rating of 4 / 10 to MICROBIX BIOSYSTEMS INC (MBX.CA). This can be considered as Fairly Valued.


What is the profitability of MBX stock?

MICROBIX BIOSYSTEMS INC (MBX.CA) has a profitability rating of 3 / 10.